Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
2 vehicles on file, newest listing first
1 of 12 appear on more than one
David A. Berry is a serial entrepreneur, inventor, and investor who currently serves as Co-Founder and Managing Partner of Averin, a venture firm focused on leveraging technology to transform industries, and as Chief Executive Officer of Averin Capital Acquisition Corp. (NASDAQ: ACAAU), a special purpose acquisition company that completed its IPO on February 19, 2026, raising approximately $283.86 million in proceeds with Deutsche Bank as left-lead underwriter. The SPAC is structured with a 24-month tenor plus a 3-month extension, holds 100% of IPO cash in trust, and targets the technology sector on a global basis. Berry's role at the SPAC leverages his deep experience as a company builder: he has founded over 30 companies, including seven that have been valued at over $1 billion, and he holds more than 200 patents. He is listed as a speaker at the Milken Institute's Asia Summit 2025, where he is participating on a panel examining whether AI can deliver better, faster, and cheaper healthcare.
Prior to co-founding Averin, Berry was a General Partner at Flagship Pioneering, the prominent life sciences venture firm, where he built and incubated multiple companies. He was also the founder and CEO of Valo Health, an AI-driven drug discovery company, where he raised over $500 million in capital and executed a transformative partnership with Novo Nordisk. At Averin, he works closely with portfolio companies including Biolinq, reflecting his continued focus on biotechnology and synthetic biology ventures. His career has been defined by a pattern of founding, scaling, and exiting companies at the intersection of biology, engineering, and computation, establishing him as one of the most prolific company builders in the life sciences and technology sectors.
Berry's academic credentials are exceptional and directly underpin his work at the frontier of biological engineering. He earned his M.D. from Harvard Medical School and his Ph.D. from the Massachusetts Institute of Technology through the biological engineering division, where he conducted research under Professors Robert Langer and Ram Sasisekharan, two of the most influential figures in biomedical engineering and glycobiology, respectively. This combined medical and engineering training has informed his approach to company creation, enabling him to identify and commercialize scientific breakthroughs across therapeutics, diagnostics, and platform technologies. His LinkedIn profile describes him as a founder, entrepreneur, investor, innovator, and inventor who has built over 20 companies including seven reaching billion-dollar valuations, consistent with his broader reputation as a career innovator driven by the power of technology to transform industries.
This record is keyed to SEC CIK 0001204876 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 23 institutional-holder rows on these vehicles, under 15 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.